Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 11/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397658 | 0.84 | GCG (0.51) | GCG | |
| SCHEMBL3402110 | 0.82 | CNR1 (0.39) | GCGMCL1PTGS1PTGS2POLB | |
| SCHEMBL3407767 | 0.76 | LMNA (0.45) | GCGMCL1PTGS2SMN1; SMN2KDM4E | |
| SCHEMBL719589 | 0.76 | NPC1 (0.48) | PTGS1PTGS2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3400803 | 0.76 | NPC1 (0.47) | PTGS1PTGS2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL720851 | 0.75 | GCG (0.54) | GCGNPC1RAB9A | |
| SCHEMBL721057 | 0.75 | MAOB (0.41) | GCGPOLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL716872 | 0.74 | MCL1 (0.47) | MCL1POLBKDM4EALDH1A1NPC1 | |
| SCHEMBL719401 | 0.73 | MCL1 (0.38) | GCGMCL1POLBSMN1; SMN2KDM4E | |
| SCHEMBL718505 | 0.73 | NPC1 (0.42) | PTGS1PTGS2SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885MCL1 900/4885PTGS1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.